GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth
When oncologists received a geriatric assessment summary with management recommendations for patients aged 70 or over, grade 3-5 toxicity fell from 71% to 51% with no loss in survival.
GAP70+ was a cluster-randomised trial in 40 US community oncology practices. Patients aged 70 or over with advanced cancer and at least one impaired geriatric domain who were starting a new palliative chemotherapy or other high-risk regimen were enrolled (718 patients). Intervention practices received a geriatric assessment summary and tailored recommendations; usual-care practices received only alerts for depression and cognitive impairment.
The primary endpoint, grade 3-5 toxicity over 3 months, occurred in 51% of intervention patients versus 71% in usual care (relative risk 0.74). Oncologists in the intervention arm more often reduced dose intensity at cycle 1, and 6-month and 1-year survival did not differ. A companion trial (GAIN, JAMA Oncology 2021) found a similar toxicity reduction.
The result made geriatric assessment-guided management a guideline standard (ASCO 2023) for older adults receiving systemic therapy.
- Grade 3-5 toxic effects 51% vs 71% (relative risk 0.74, 95% CI 0.64-0.86)
- Cycle 1 dose reduction 49% vs 35% in the intervention arm
- No difference in 6-month overall survival (71% vs 74%) or 1-year survival
- Falls and polypharmacy-related events were also reduced with geriatric management
Older patients are more likely to be harmed by standard-dose chemotherapy, and a structured assessment of function, cognition, nutrition and social support lets oncologists adjust treatment safely. Starting lower does not appear to shorten life. Most older patients still do not get such an assessment.
- Cluster randomisation at practice level with modest numbers per practice
- Toxicity was the primary endpoint; quality-of-life and functional outcomes were secondary
- Intervention effect depends on oncologists acting on recommendations; adherence varied
- Excludes curative-intent settings, where dose reductions are riskier
Pages like this
not linked directly; found by shared links- IdeaAn automatic electronic frailty index inside the oncology record
Shares Geriatric assessment by default for every patient over 70 starting cancer treatment, Geriatric assessment, Older and multimorbid patients are excluded and undertreated.
- IdeaA mandatory over-70s cohort with geriatric assessment in every pivotal trial
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated, Wrong doses.
- InstitutionWilmot Cancer Institute, University of Rochester
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated, Toxicity and quality of life are undervalued.
- IdeaGeriatrician co-management for older patients having cancer surgery
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated.
- IdeaParallel real-world cohorts for sicker patients alongside every pivotal trial
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated.
- IdeaStop screening by life expectancy, not birthday, with a tool in the record
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated.
- IdeaPragmatic trials in patients over 75 with function, not just survival, as the primary endpoint
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated.
- IdeaA defined pathway for patients with both dementia and cancer
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated.